These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 24468835)
81. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419 [TBL] [Abstract][Full Text] [Related]
82. Chinese Medicine Treatment on Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Wu XL; Zhuang HF; Zhao YN; Yu XL; Dai TY; Gao RL Chin J Integr Med; 2020 May; 26(5):324-329. PubMed ID: 32350801 [TBL] [Abstract][Full Text] [Related]
83. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation. Fuji S; Byrne M; Nagler A; Mohty M; Savani BN Bone Marrow Transplant; 2021 Jun; 56(6):1248-1256. PubMed ID: 33514922 [TBL] [Abstract][Full Text] [Related]
84. The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Schroeder MA; Choi J; Staser K; DiPersio JF Biol Blood Marrow Transplant; 2018 Jun; 24(6):1125-1134. PubMed ID: 29289756 [TBL] [Abstract][Full Text] [Related]
85. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415 [TBL] [Abstract][Full Text] [Related]
87. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Foss FM Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113 [TBL] [Abstract][Full Text] [Related]
88. Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation. Tian L; Ogretmen B; Chung BY; Yu XZ Front Immunol; 2022; 13():904823. PubMed ID: 36052066 [TBL] [Abstract][Full Text] [Related]
89. Novel therapies for graft versus host disease with a focus on cell therapies. Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG Front Immunol; 2023; 14():1241068. PubMed ID: 37868964 [TBL] [Abstract][Full Text] [Related]
90. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R; Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417 [TBL] [Abstract][Full Text] [Related]
91. [Treatment of graft-versus-host disease]. Ozawa Y Rinsho Ketsueki; 2020; 61(9):1395-1401. PubMed ID: 33162541 [TBL] [Abstract][Full Text] [Related]
92. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL; Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425 [TBL] [Abstract][Full Text] [Related]
93. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study. Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556 [TBL] [Abstract][Full Text] [Related]
95. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528 [TBL] [Abstract][Full Text] [Related]
96. Current Advances in Graft-versus-host Disease After Intestinal Transplantation. Oza K; Kang J; Patil D; Owen KL; Cui W; Khan K; Kaufman SS; Kroemer A Transplantation; 2024 Feb; 108(2):399-408. PubMed ID: 37309025 [TBL] [Abstract][Full Text] [Related]
97. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Jagasia M; Zeiser R; Arbushites M; Delaite P; Gadbaw B; Bubnoff NV Immunotherapy; 2018 Apr; 10(5):391-402. PubMed ID: 29316837 [TBL] [Abstract][Full Text] [Related]
98. Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker. Paczesny S Br J Haematol; 2021 Mar; 192(6):951-967. PubMed ID: 32039480 [TBL] [Abstract][Full Text] [Related]
99. Updates in chronic graft-versus-host disease. Hamilton BK Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):648-654. PubMed ID: 34889364 [TBL] [Abstract][Full Text] [Related]
100. Study design and endpoints in graft-versus-host disease. Martin PJ Best Pract Res Clin Haematol; 2008 Jun; 21(2):357-72. PubMed ID: 18503998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]